Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alessia Preziosi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced Detection of BRCA Copy Number Alterations Within a Commercial HRD Assay: Implications for Precision Oncology in Ovarian Cancer

    by Maria De Bonis, Pierluigi Iapicca, Elisa De Paolis, Francesca Brisighelli, Jessica Evangelista, Alessia Perrucci, Claudio Ricciardi Tenore, Giulia Maneri, Paola Concolino, Alessia Piermattei, et al.

    Large genomic rearrangements (LGRs), occurring as copy number alterations (CNAs), represent a clinically relevant class of pathogenic or likely pathogenic variants (P LPVs) in BRCA1/2 (BRCA) genes in ovarian cancer (OC). We evaluated the performance of a high-resolution algorithm integrated into a commercial homologous recombination deficiency (HRD) assay to improve the identification of clinically actionable CNAs in BRCA genes by formalin-fixed paraffin-embedded (FFPE) samples. A total of 760 OC samples were analyzed using a commercial HRD assay incorporating a bioinformatics algorithm for CNA detection. The algorithm was additionally applied to additional homologous recombination repair (HRR) genes, and associations between CNA events and genomic instability (GI) were evaluated. The algorithm demonstrated high sensitivity for both gene and exon-level CNA. The high correlation between CNA positivity cases and GI, in the absence of P/LPVs BRCA single-nucleotide or indels variants, emphasizes the value of integrating CNA detection into routine HRD testing workflows. The extended analysis of additional HRR genes enabled broader characterization of clinically relevant CNAs. This study enables reliable identification of clinically relevant BRCA LGRs from FFPE within HRD testing, supporting a tumor-first diagnostic strategy. This approach may expand the identification of OC patients potentially eligible for PARP inhibitor therapy.

  • Open Access

    Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result in BRCA1 Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay

    by Paola Concolino, Elisa De Paolis, Martina Rinelli, Giulia Maneri, Francesca Brisighelli, Rita Trozzi, Simona Duranti, Luciano Giacò, Maria Piane, Alessia Preziosi, et al.

    Paola Concolino, M.Sc., Elisa De Paolis, M.Sc., Martina Rinelli, M.Sc., Giulia Maneri, M.Sc., Francesca Brisighelli, Ph.D., Rita Trozzi, M.D., Simona Duranti, M.D., Luciano Giacò, M.Sc., Maria Piane, M.D., Alessia Preziosi, M.Sc., Arianna Panfili, M.D., Giovanni Scambia, M.D., Camilla Nero, M.D., Maria De Bonis, M.Sc., and Angelo Minucci M.Sc., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0051


  • Open Access

    Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice

    by Serena Dotolo, Riziero Esposito Abate, Cristin Roma, Davide Guido, Alessia Preziosi, Beatrice Tropea, Fernando Palluzzi, Luciano Giacò, Nicola Normanno

    The use of next-generation sequencing (NGS) techniques for variant detection has become increasingly important in clinical research and in clinical practice in oncology. Many cancer patients are currently being treated in clinical practice or in clinical trials with drugs directed against specific genomic alterations. In this scenario, the development of reliable and reproducible bioinformatics tools is essential to derive information on the molecular characteristics of each patient’s tumor from the NGS data. The development of bioinformatics pipelines based on the use of machine learning and statistical methods is even more relevant for the determination of complex biomarkers. In this review, we describe some important technologies, computational algorithms and models that can be applied to NGS data from Whole Genome to Targeted Sequencing, to address the problem of finding complex cancer-associated biomarkers. In addition, we explore the future perspectives and challenges faced by bioinformatics for precision medicine both at a molecular and clinical level, with a focus on an emerging complex biomarker such as homologous recombination deficiency (HRD).